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Designing Irreversible Inhibitors – Worth the Effort? 
Concepción González-Bello*[a] 
 
Abstract: Despite the unquestionable success of numerous 
irreversible drugs in clinical use, such as aspirin and penicillin, the 
number of approved drugs in comparison with non-covalent ones is 
relatively low. Over the years, the possible off-target effects of these 
types of compounds have been the major concern that has 
hampered their development. However, their remarkable advantages 
over non-covalent drugs and a better analysis of the risks have 
reduced the widespread skepticism surrounding them. The design of 
irreversible inhibitors is a challenge, particularly considering that in 
some cases their efficacy is due to complex and unexpected 
mechanisms of action. In this article the main advantages of 
irreversible inhibition are summarized and the complexity of certain 
covalent modification mechanisms is highlighted with selected 
examples.  
Introduction 
Many of the most widely employed and successful drugs in 
clinical use are irreversible drugs.[1-8] Aspirin, which was 
developed by Bayer in 1897 as an anti-inflammatory agent, is 
probably the best known example. As with many other examples, 
the covalent mechanism of action of Aspirin was discovered by 
serendipity more than 70 years after its commercialization. 
Aspirin causes the irreversible inhibition of cyclooxygenases 1 
(COX-1) and 2 (COX-2), which are enzymes involved in the 
prostaglandin biosynthesis, by acylation of a serine residue that 
is close to the active site.[9,10] Other examples are penicillins and 
cephalosporins,[7] which are antibiotics that inhibit the cross-
linking of bacterial cell walls catalyzed by penicillin-binding 
proteins (Figure 1). Fosfomycin,[11-13] which is an antibiotic that 
targets MurA, an enzyme involved in peptidoglycan biosynthesis, 
and omeprazole, which is a proton pump inhibitor for the 
treatment of diverse stomach diseases, are further examples.[14] 
Despite this success, the number of approved irreversible drugs 
is paradoxically relatively low in comparison with the 
commercially available non-covalent drugs.[1,2] The complexity in 
designing effective covalent inhibitors of a selected target and, 
more importantly, their selectivity, were the major concerns that 
slowed their development. The hepatotoxic properties reported 
in the 1970s for some compounds probably contributed greatly 
to the increased concern in subsequent years.[2]  
 
Figure 1. Examples of irreversible drugs.
 
Fortunately, irreversible inhibitors have started to be seen in a 
more favorable light in recent years. The advantages of 
irreversible drugs, their high economical profitability and an 
improved understanding of the potential risks have resulted in a 
clear increase in the number of compounds in clinical trials, drug 
approvals and scientific articles in this area.[1,2] The clinical 
relevance of irreversible drugs have been reviewed previously 
and these aspects will be briefly summarized here.[1-6] 
Considering the fact that the covalent mechanisms of most 
irreversible drugs in clinical use were found out many years after 
their discovery, a knowledge of the chemical modification 
mechanism of irreversible inhibitors and the structural basis of 
their efficiency could facilitate the future design of more efficient 
inhibitors and/or inspire the development of novel inhibitors to 
target unexplored enzymes.[15] This article illustrates the 
complex mechanism of action of some of the irreversible 
inhibitors. This may provide inspiration for future inhibitor design. 
Structural details of the modified targets to support the covalent 
mechanism are also provided. 
Irreversible Inhibitors 
Irreversible inhibitors are small molecules that initially bind at the 
active site of a target and then react with it by forming a stable 
covalent adduct. These compounds usually contain an 
electrophilic functional group that reacts with a nucleophilic 
group of a side chain residue present in the active site of the 
enzyme. Although examples of irreversible inhibitors that target 
receptors have been reported, as clopidogrel (Figure 1), which is 
an antiplatelet drug that inhibits the P2Y purinergic receptor, [16] 
most of these targets are enzymes. In the latter case, the initial 
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enzyme-inhibitor complex (E--I) is converted into an enzyme-
adduct complex (E–I*) that does not have catalytic activity 
(Scheme 1). In general, irreversible inhibitors of enzymes are 
usually designed to react with the key residues for catalysis, 
which are located in the active site. However, there are also 
excellent examples of allosteric irreversible inhibitors, in 
particular, of oncology and anti-infective targets.[17-22] These 
compounds act by avoiding the correct geometry of the active 
site for catalysis, which is achieved by covalent modification of 
another region of the target. 
 
Scheme 1. Irreversible inhibition.
 
In principle, these types of inhibitors can achieve full inactivation 
of the target when they are left for a sufficient time because the 
target would be permanently blocked by the inhibitor. Thus, the 
dissociation equilibrium observed for non-covalent inhibitors, 
which interact with the target through reversible forces, does not 
occur. This makes irreversible inhibitors more efficient and 
robust against pharmacokinetic liabilities (clearance, binding to 
serum proteins, etc.) than non-covalent ones. Moreover, as non-
equilibrium binding takes place, a time-dependent kinetic is 
produced since the amount of active target decreases 
progressively as the reaction between the target and the 
inhibitor occurs. Considering that the rate of this reaction is 
relatively slow (minutes or more) whereas the association 
process in non-covalent inhibition is usually quite fast (seconds 
or less), the inhibition potency of irreversible inhibitors is not 
quoted as an IC50 value – in contrast to the non-covalent 
systems. The IC50 values would strongly depend on the pre-
incubation time and the efficiency of the chemical reaction (rate). 
Instead, the inhibitory potency is more precisely described by 
rate of inactivation (kinact) and inhibition constant (Ki) terms.
[23] 
The design of an irreversible inhibitor is a challenge in the sense 
that it requires a combination of two key factors in the same 
molecule: binding and reactivity. Thus, as for non-covalent 
inhibitors, a high affinity for the enzyme is required in order to 
achieve selectivity and an effective concentration of the enzyme-
inhibitor complex. In addition to the latter, the two reactive 
centers (nucleophile and electrophile) must be located in close 
contact and in the correct geometry for the transformation to 
occur. In this regard, it is important to highlight that enzyme 
active sites are usually shielded from the solvent environment, 
normally by a substrate-covering loop that closes over the active 
site after substrate binding. In this arrangement, the reactive 
nucleophilic side chain residues are quite desolvated and a high 
effective concentration of the nucleophile or a base is achieved. 
This is an amazing way that Nature has found to address 
mechanistically challenging transformations like the formation of 
carbon-carbon bonds through covalent catalysis. To some 
extent, irreversible inhibitors are designed to imitate Nature. 
The advantages of covalent drugs are:[1-6]  
 Increased efficiency that favors the use of lower doses and 
the reduction of the side effects;  
 Selectivity; 
 Reduced risk of drug resistance due to active site residue 
changes, which is a major concern in the treatment of 
infectious diseases and oncology;  
 Reduced sensitivity to pharmacokinetic parameters since the 
inhibitor is covalently attached to the target; 
 Prolonged duration of the inhibition since the activity can 
only be recovered by synthesis of new target; 
The disadvantages of covalent drugs are:[1-6]  
 Low specificity leading to side effects such as hepatotoxicity, 
mutagenicity or carcinogenicity. 
 Potential immunogenicity of the resulting target-adduct, 
which could cause an allergic response or drug 
hypersensitivity reaction.  
An analysis of thirty nine irreversible drugs, which were 
approved by the US Food and Drug Administration (FDA), 
carried out by Singh et al.[1] in 2011 showed that irreversible 
drugs are mainly applied in anti-infective (33%) and oncology 
therapies (20%) (Figure 2). 15% are used for gastrointestinal 
disorders, 10% for central nervous system diseases, 5% for 
cardiovascular disorders and 3% for inflammation diseases. The 
use of irreversible inhibitors for chronic diseases is limited due to 
the high risk of an immune response of the resulted target-
adduct after continuous treatment. It is not therefore surprising 
that over 50% of these compounds were developed for oncology 
and infective diseases. 
 
Figure 2. Distribution of approved irreversible drugs in therapeutic areas. Data 
from an analysis of 39 approved drugs by the US Food and Drug 
Administration (FDA).
[1] 
The most frequent electrophilic functional groups present in 
covalent inhibitors are α,β-unsaturated ketones, vinyl sulfones, 
α-substituted carbonyl derivatives, bromodihydroisoxazoles, 
imidazole-1-carboxamides, epoxides, β-lactams and strained 
lactones (Figure 3).[24,2] In a recent study on the selectivity of 
diverse electrophilic groups toward several relevant targets, Jöst 
et al.[19] showed that these functional groups are much less 
promiscuous, i.e., more selective, than initially thought. They 
studied the binding of six electrophiles (acrylamides, 
chloroacetylamides, dimethylsulfoniumacetylamides, 
bromodihydroisoxazoles, 2-cyanoacetamides, and imidazole-1-
carboxamides) towards eleven structurally and functionally 
diverse enzyme targets. Specifically, seven bacterial targets 






(MurA-F, bacterial methionine aminopeptidase), two viral (denge 
virus protease, West Nile virus protease) and two human ones 
(thrombin, human methionine aminopeptidase type I). 
Unexpectectly, chloroacetamides, which are the most 
electrophilic functional groups of the series, showed low off-
target reactivity. Along with acryl- and 2-cyanoacetamides and 
imidazole-1-carboxamides proved to be good functional groups 
for the design of covalent inhibitors. The 3-bromo-4,5-
dihydroisoxazole moiety, which is derived from the natural 
product acivicin and reacting by nucleophilic replacement of the 
bromine, proved to be a particularly selective group for antibiotic 
designs as showed some activity with the Mur enzymes.  
 
Figure 3. Examples of electrophilic functional groups typically present in 
irreversible inhibitors.
 
Chemical Modification Mechanism - Selected 
Examples 
There are numerous relevant irreversible inhibitors in which the 
compound only undergoes direct attack by the nucleophilic 
group of a side chain residue present in the active site to the 
electrophilic center of the inhibitor. That is the case in several 
kinase enzymes in which the electrophilic group of the inhibitor 
is an α,β-unsaturated ketone or a vinyl sulfone,[26-29] in bacterial 
transcriptional activator LasR, which is inhibited by 
haloacetamides derived from its natural autoinducer (N-acyl 
homoserine lactones)[30] and in glyceraldehyde-3-phosphate 
dehydrogenase, which is covalently modified by 
halodihydroisoxazoles,[31] among others. From the design point 
of view, such inhibitors are less complex because they do not 
undergo further, and probably unexpected, transformations. 
However, in other cases the efficiency of the inhibitor is due to 
several chemical modifications. For instance, further reactions 
after covalent linkage with the enzyme take place or the inhibitor 
undergoes diverse intramolecular reactions to generate the 
reactive species that finally modifies the enzyme. Selected 
examples of the latter type will be discussed in this section. In 
particular, irreversible inhibitors that target oxacillinases (class D 
β-lactamases), type I dehydroquinase, and H+/K+ ATPase 
hydrogen/potassium-exchanging ATPase are discussed. 
Oxacillinases 
β-Lactamases (EC 3.5.2.6) are enzymes that hydrolyze the most 
widely used antibiotics, i.e., β-lactams, in an acylation-
deacylation-based process that represents the most prevalent 
cause of antibiotic resistance in Gram-negative bacteria. Among 
the four major β-lactamase classes (A, B, C and D), class D 
enzymes, which are also known as ‘oxacillinases’ (OXA), are the 
most rapidly growing and diverse group of enzymes.[32-36] These 
enzymes hydrolyze penicillins, extended spectrum 
cephalosporins, and aztreonam (Figure 4A). Recently, a new 
type of oxacillinase that is also resistant to carbapenems, such 
as imipenem, has been identified and are widely dispersed in 
some clinically relevant species.[37-40]  
 
Figure 4. Most relevant β-lactam antibiotics (A) and selected β-
lactamases inhibitors (B) in clinical use. The modified positions of 1 that 
afforded inhibitors of improved properties are highlighted with arrows. 
Current β-lactamase inhibitors in clinical use include penicillin 
sulfones such as sulbactam (1), tazobactam (2), and clavulanic 
acid (3) (Figure 4B). As with β-lactam antibiotics, the mechanism 
of action of these inhibitors starts with the nucleophilic β-lactam 
ring opening by the catalytic serine to afford an acyl-enzyme 
adduct 4 (Scheme 2).[41,42] The resulting secondary amine in 4 
triggers the dioxothiazolidine ring opening to give adduct 5. The 
latter process does not take place with β-lactam antibiotics such 
as penicillin. Presumably, the driving force for this ring opening 
reaction is the formation of a good leaving group, a sulfinate vs a 
sulfide for the β-lactam antibiotics. The extra electrostatic 
interactions of the resulted sulfinate group also enhance their 
binding.  







Scheme 2. Mechanism of action of penicillin sulfones 1 and 2. 
However, these commercially available inhibitors mainly proved 
to be useful for the inactivation of class A β-lactamases because 
the resulting adduct 5 can also undergo further transformations 
involving other residues in the active site that are susceptible to 
change by the enzyme. Thus, adduct 5 can tautomerize to give 
β-aminoacrylate adduct 6, which was observed by X-ray 
crystallography [PDB entries 1VM1 (2.0 Å),[43] 2H5S (1.3 Å)[44]], 
or undergo conjugated nucleophilic addition by a second serine, 
which is also located in the active site, to give adduct 7.[37] 
Subsequent β-elimination and hydrolysis affords adduct 8, which 
was also observed experimentally by X-ray crystallography.[37] 
Among the developed inhibitors against carbapenem-
hydrolyzing class D β-lactamases, it is worth highlighting 1,1-
dioxo-6(Z)-(2-pyridyl)methylenepenicillanic acid (9a), which was 
first reported by Chen et al.[45] from Pfizer (Figure 5). It was 
shown that the incorporation of a (2-pyridyl)methylene group at 
C6 of the sulbactam results in increased inhibitory potency 
against β-lactamases from S. aureus and E. coli (low micromolar 
range). More importantly, the authors related the increased 
efficiency of this inhibitor with the formation of a heterocyclic 
ester derivative that is resistant to hydrolysis. The inhibitory 
properties of 9a were further improved by introducing a catechol 
ester (9b), a ((2-aminothiazol-4-yl)methyl)carbamate (9c) or a 
(2-aminoethyl)carbamate group (9d).[46,47] Derivative 9c proved 
to have the lowest Ki value (500 nM), whereas inhibitor 9b had 
the highest inactivation efficiency, with a kinact/Ki of 0.21 µM
–1 s–1. 
Moreover, the catechol moiety in 9b also facilitated entry 
through the outer membrane via the iron-uptake cell pathway.[47]  
 
Figure 5. Selected inhibitors of carbapenem-hydrolyzing class D β-lactamases. 
The crystal structure of OXA-24 from A. baumannii 
covalently modified by 9d (PDB entry 3FZC, 2.0 Å) showed 
that the ligand is covalently linked to the catalytic Ser81 as 
an indolizine ester (Figure 6).[49] The ligand is also fixed in 
the active site by a series of strong interactions that further 
increase the stability of the complex. Specifically, the 
sulfinate group is anchored in the active site by a salt bridge 
with the guanidinium group of Arg261, two hydrogen-
bonding interactions with the side chains of highly 
conserved Ser128 and Ser219 and an electrostatic 
interaction with Lys218. In addition, the carboxylate group, 
which as for β-lactam antibiotics proved to be essential for 
activity, establishes a strong hydrogen-bonding interaction 
with the phenol group of Tyr112. The formation of the 
indolizine adduct 12 would occur due to the favorable 
positioning of the pyridine nitrogen for nucleophilic attack on 
the conjugated imine adduct 11 that would result from 
dioxothiazolidine ring opening.[49] (2-
Pyridyl)methylenecephalosporins also have a similar 
covalent mechanism, whereas 7-(tert-
butoxycarbonyl)methylenecephalosporsin sulfone gives an 
eight-membered adduct.[50,51] The increased potency of 
compounds 9, in comparison to the aforementioned 
penicillin sulfones 12, against a wide range of β-
lactamases seems to be due to the higher stability of the 
resulting heterocyclic ester as well as a set of favorable 
interactions that prevent hydrolysis of adduct 12. 
Type I Dehydroquinase 
The increasing and widespread development of resistance to 
antibiotics in both community and clinical settings, along with the 
evident decline in antibiotic research by the major 
pharmaceutical companies during the last 50 years, has recently 
triggered the search for new antibiotics and alternative therapies. 
In particular, a great deal of effort has been devoted to the 
development of compounds that target bacterial virulence. The 
inhibition of virulence factors will lead to a loss of the ability to 
cause infection in the host and, as a consequence, they should 
be more easily eliminated by the immune system.[52-55] Anti-
virulence drugs will disarm bacteria and create an in vivo 
scenario similar to that achieved by vaccination with a live 
attenuated strain. In comparison with antibiotic therapies, which 
target bacterial survival, the anti-virulence strategy would not 






cause substantial stress to the bacterium, which is one of the 
causes of the growing emergence of antibiotic-resistant strains. 
 
Figure 6. (A) Proposed mechanism for the covalent modification of OXA-24 
caused by inhibitors 9bd and (B) detail view of the active site of OXA-24 from 
A. baumannii covalently modified by irreversible inhibitor 9d (PDB entry 3FZC, 
2.0 Å)
[49]
. Hydrogen bonding and electrostatic interactions between the ligand 
and the OXA-24 enzyme are shown. Relevant side chain residues are shown 
and labeled. 
A promising target for the development of new anti-virulence 
agents is the type I dehydroquinase enzyme (3-dehydroquinate 
dehydratase, EC 4.2.1.10, DHQ1) because it seems to act as a 
virulence factor in vivo.[56-59] DHQ1 catalyzes the reversible 
dehydration of 3-dehydroquinic acid (13) to afford 3-
dehydroshikimic acid (14) involving the formation of several 
Schiff base species’ with an essential lysine (Lys170 in S. typhi) 
(Figure 7). The final dehydratation step is mediated by an 
essential histidine (His143 in S. typhi) acting as a proton 
donor.[60-63] Computational studies carried out on the Michaelis 
complex of DHQ1 from S. typhi (St-DHQ1) suggest that the 
formation of the substrate-Schiff base occurs by activation of the 
oxygen atom of the ketone group in 13 by the essential histidine, 
followed by nucleophilic attack from the ketone Si face by the 
essential lysine.[64,65] Based on the mechanism of action, a 
mimetic of the natural substrate that does not bear such reactive 
functional groups, namely ammonium derivative 15, was 
recently developed (Figure 7).[66] This compound proved to be a 
time-dependent irreversible inhibitor of DHQ1 from S. aureus 
(Sa-DHQ1) and St-DHQ1, but with some differences in the 
formation of the resulting adducts. 
 
Figure 7. Reaction catalyzed by DHQ1 and irreversible inhibitors 1516. 
In the case of St-DHQ1, the crystal structure of the St-DHQ1/15 
adduct (PDB entry 4UIO, 1.35 Å),[66] which was obtained by 
soaking apo-St-DHQ1 crystals, showed that the ligand is 
covalently linked to Lys170 as an amine (Figure 8A). This 
chemical modification would occur by activation of the essential 
histidine and subsequent nucleophilic attack by the essential 
lysine with the release of ammonia (Scheme 3). Further 
chemical modifications of adduct 17, which involved 
dehydration/aromatization reactions and the formation of Schiff 
base species’, were detected by MALDI-MS. The crystal 
structure of the St-DHQ1 obtained after several weeks by co-
crystallization with epoxide 16 showed that the enzyme is 
covalently modified as a stable Schiff base (PDB entry 4CLM, 
1.4 Å, Figure 8B)[65] and this suggests that ammonium derivative 
15 might also be a prodrug of epoxide 16. The results of 
computational studies suggest that the conserved Asp114 
residue would be the base that generates a hydroxide group, 
which triggers the elimination reaction by deprotonation of a 
conserved water molecule. In contrast, only adduct 17 was 
obtained in the case of Sa-DHQ1 enzyme. The replacement of 
Phe225 in St-DHQ1 by Tyr214 in Sa-DHQ1, along with its 
hydrogen-bonding interaction with a conserved water molecule, 
seems to be responsible for preventing the initial adduct 17 from 
undergoing further transformations. Ammonium derivative 15 
seems to be a good scaffold for development as it was able to 






reduce the ability of Salmonella Enteritidis to kill A549 
respiratory cells in vitro.[66] 
Hydrogen/potassium-exchanging ATPase (H+/K+ ATPase) 
High levels of gastric acid cause a wide range of stomach 
diseases, including gastroesophageal reflux disease, which can 
irritate the esophagus and cause heartburn and peptic ulcers. 
This is a common chronic disorder that affects millions of people 
in Western countries. Until the late 1970s, this disorder was 
difficult to treat and it clearly decreases the quality of life of those 
affected. Fortunately, the discovery in the late 1970s of 
cimetidine, an antagonist of the histamine 2 (H2) receptor that is 
involved in gastric acid secretion, and the subsequent 
investigations by Astra Pharmaceuticals led to the discovery of 
omeprazole (Scheme 4).[16,67-68] 
 
Figure 8. Crystal structures of St-DHQ1 covalently modified by ammonium derivative 15 (PDB entries 4UIO, 1.35 Å)
[65]
 and epoxide 16 (PDB entries 
4CLM, 1.4 Å).
[64]
 Interactions of the modified inhibitors 15 (A) and 16 (B) with St-DHQ1. Hydrogen bonding and electrostatic interactions (blue) 
between the ligand and the St-DHQ1 are shown. Relevant residues are shown and labeled. 
 
Scheme 3. Proposed covalent modification mechanism of St-DHQ1 caused by irreversible inhibitors 15 and 16. Covalent adducts 17 and 18 of St-DHQ1 have 




, respectively). For Sa-DHQ1, adduct 17 is the major species detected by MALDI-MS. 
For St-DHQ1, adduct 18 undergoes elimination/aromatization reactions and adduct I and its reduced form, II, have been detected by MALDI-MS. 







Scheme 4. Mechanism of action of omeprazole, the prodrug form of active metabolite 23. This reactive compound is generated by an intramolecular 
rearrangement followed by dehydration under the acidic conditions in the stomach. 
 
It was found that omeprazole modifies irreversibly an integral 
membrane enzyme responsible for the secretion of acid into the 
stomach, namely hydrogen/potassium-exchanging ATPase (EC 
3.6.3.10), which is also known as H+/K+ ATPase.[69] This enzyme 
catalyzes the exchange of extracytoplasmic K+ for cytosolic 
H3O
+ in a process that occurs through phosphorylation of the 
enzyme by ATP, which in turn triggers a conformational change 
in the protein that helps to drive ion transport.  
At neutral pH, omeprazole is stable and does not inhibit the 
enzyme. However, in the acidic medium of the stomach 
omeprazole undergoes an acid-promoted rearrangement that 
leads to the formation of the highly reactive cyclic sulfenamide 
23, which inhibits H+/K+ ATPase (Scheme 4).[16,67-69] The half-life 
of omeprazole at pH 1 is about 2 minutes whereas it is stable for 
around 20 hours at pH 7.4.[67] 
The proposed mechanism of action involves the initial formation 
of sulfenic acid 20 under the acidic conditions in the stomach. 
This compound subsequently undergoes an intramolecular 
cyclization initiated by nucleophilic attack of the pyridine nitrogen 
atom in 20 on the C2 carbon of the benzimidazole moiety. The 
resulting compound 21 undergoes intramolecular nucleophilic 
attack of one of the nitrogen atoms of the benzimidazole moiety 
with elimination of water to give the highly reactive cyclic 
sulfenamide 23, which is the active inhibitor formed in vivo from 
omeprazole. Finally, compound 23 undergoes nucleophilic 
attack by the Cys813 side chain to afford a stable disulfide 
adduct that causes inhibition of the enzyme.[70] Although, the two 
enantiomers of omeprazole has similar inhibitory potency, the S 
enantiomer (esomeprazole), proved to have better bioavailability 
and oral potency. This compound is commercialized as 
Nexium®.[71,72] 
Conclusions and Outlook 
For many years, irreversible inhibitors have not been a high 
priority in the pharmaceutical industry. This general skepticism 
was triggered by the discovery of the unexpected covalent 
mechanisms of successful drugs after many years of use and, 
more importantly, after hepatotoxic properties were reported in 
the 1970s for some compounds. These two factors retarded the 
development of irreversible systems over the subsequent years. 
The efficacy and selectivity shown by widely used and 
successful drugs in clinic use over the years, e.g., penicillin, 
aspirin and omeprazole, suggests that there was a kind of 
‘blindspot’ when assessing the real risks of this type of 
compound. Fortunately, the attitude towards irreversible 
inhibitors has changed. Probably, we all agree that the potential 
toxicity of irreversible inhibitors vs the non-covalent ones is 
much higher. Mainly due to the higher risks in: 1) the possible 
formation of non-selective or non-specific covalent adducts with 
off-target proteins; and 2) the potential immune reactions. 
However, their potential in non-chronic therapies, such as 
oncology and infectious diseases, is evident considering the 
numerous successful examples in clinical use over the years. 
Moreover, a better analysis of the risks and the recognized 
advantages of irreversible inhibitors over the non-covalent 
systems has resulted in a clear increase in the number of 
approved irreversible drugs, of compounds in clinical trials and 
in the number of scientific articles in this area. 






The design of a covalent inhibitor is challenging because, in 
addition to a high affinity for the enzyme, it requires an efficient 
reaction, which implies a suitable arrangement of the reactive 
centers in both the inhibitor and the enzyme. From the synthetic 
point of view, if we want to perform such reaction in the 
laboratory, it would probably be impossible. Specially, if we 
consider that the ligand might have other groups such as 
hydroxyl or carboxylate groups to achieve good solubility in 
aqueous media, which also react with the selected electrophilic 
reagent. Also, it would normally require the use of highly reactive 
electrophilic groups that would be too reactive to be even 
considered in any medicinal chemistry program. However, by 
designing a ligand with high affinity for the selected therapeutic 
target, less reactive electrophilic groups, which under standard 
conditions would be unreactive, become efficient. A good 
example is the herein highlighted ammonium derivative 15 that 
reacts with an essential lysine by forming an amino adduct with 
the release of ammonia. Such less reactive and safer functional 
groups would enhance inhibitor specificity and reduce potential 
off-target effects. Therefore, for an irreversible approach, by 
achieving an exquisite anchoring of the ligand to the active site, 
i.e. “geometric perfection”, is possible to use less reactive 
electrophilic groups and thereby to reduce inhibitor toxicity. More 
work must be done in exploring alternative less reactive groups 
to be incorporated into ligand design that would be a step 
forward in this area. Furthermore, in many cases the 
effectiveness of inhibitors is due to additional reactions, which 
are sometimes difficult to predict – as discussed in this review 
with selected examples. However, the increased selectivity and 
efficiency of covalent inhibitors, their prolonged effects and the 
reduced risk of drug resistance are unique benefits that make 
their development worthwhile, specially in oncology and anti-
infectives. The knowledge in atomic detail of the covalent 
mechanisms of these inhibitors, the mechanism of action of the 
enzymes targeted by them, and further studies of the potential 
toxicity of the typically used electrophilic functional groups 
present in covalent inhibitors should make a positive contribution 
to future designs. Moreover, the development of proactive 
approaches could also contribute to reduce the potential toxicity 
of these compounds. 
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